

# The 2008 WHO diagnostic criteria for polycythemia vera primary myelofibrosis

Current Hematologic Malignancy Reports

4, 33-40

DOI: [10.1007/s11899-009-0005-6](https://doi.org/10.1007/s11899-009-0005-6)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies. <i>Clinical Epigenetics</i> , 2011, 2, 197-212.	1.8	36
2	Emerging drugs for myelofibrosis. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 555-570.	1.0	4
3	Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2012, 53, 441-444.	0.6	46
4	A clinical analysis of erythrocytapheresis for the treatment of polycythemia. <i>Transfusion and Apheresis Science</i> , 2013, 48, 229-233.	0.5	6
5	Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. <i>Leukemia</i> , 2013, 27, 1953-1958.	3.3	62
6	Hemangioblastomas and Neurogenic Polyglobulia. <i>Neurosurgery</i> , 2013, 72, 930-935.	0.6	13
7	Chorea disclosing a polycythemia vera. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 563.	1.0	10
8	Vertebral artery thrombosis: a rare presentation of primary polycythaemia. <i>BMJ Case Reports</i> , 2014, 2014, bcr2013201347-bcr2013201347.	0.2	2
9	A Multiplex Snapback Primer System for the Enrichment and Detection of JAK2V617F and MPLW515L/K Mutations in Philadelphia-Negative Myeloproliferative Neoplasms. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	6
10	Primary thrombocytosis in children. <i>Haematologica</i> , 2014, 99, 620-628.	1.7	44
11	A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms. <i>Annals of Hematology</i> , 2014, 93, 609-616.	0.8	5
12	Rethinking the diagnostic criteria of polycythemia vera. <i>Leukemia</i> , 2014, 28, 1191-1195.	3.3	52
14	The role of parathyroidectomy in JAK2 mutation negative polycythemia vera. <i>International Journal of Hematology</i> , 2014, 100, 615-618.	0.7	3
15	Out with the bad and in with the good; red cell exchange, white cell reduction, and platelet reduction. <i>Journal of Clinical Apheresis</i> , 2014, 29, 220-227.	0.7	10
16	Differenzialdiagnose <i>BCR-ABL1</i> -negativer myeloproliferativer Neoplasien. <i>Laboratoriums Medizin</i> , 2015, 39, 301-310.	0.1	0
18	Thrombotic risk assessment in 185 WHO-defined essential thrombocythemia patients: single center experience. <i>Wspolczesna Onkologia</i> , 2015, 5, 396-399.	0.7	2
19	Bone morbidity in chronic myeloproliferative neoplasms. <i>Expert Review of Hematology</i> , 2015, 8, 447-456.	1.0	8
20	Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2015, 26, v85-v99.	0.6	105

#	ARTICLE	IF	CITATIONS
21	Subfoveal Choroidal Thickness Is Associated with Blood Hematocrit Level. <i>Ophthalmologica</i> , 2015, 234, 55-59.	1.0	7
22	Bone geometry, bone mineral density, and micro-architecture in patients with myelofibrosis: a cross-sectional study using DXA, HR-pQCT, and bone turnover markers. <i>International Journal of Hematology</i> , 2015, 102, 67-75.	0.7	11
23	Factors predisposing to acquired von Willebrand syndrome during the course of polycythemia vera â€” retrospective analysis of 142 consecutive cases. <i>Thrombosis Research</i> , 2015, 136, 754-757.	0.8	21
24	Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. <i>Blood Cancer Journal</i> , 2015, 5, e337-e337.	2.8	100
25	The Calreticulin gene and myeloproliferative neoplasms. <i>Journal of Clinical Pathology</i> , 2016, 69, 841-845.	1.0	12
26	Elevated Hemoglobin or Hematocrit Level. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2225.	3.8	2
27	Unbiased pro-thrombotic features at diagnosis in 977 thrombocytopenic patients with Philadelphia-negative chronic myeloproliferative neoplasms. <i>Leukemia Research</i> , 2016, 46, 18-25.	0.4	13
28	A Clue in JAK2: Masked Polycythemia Vera. <i>American Journal of Medicine</i> , 2016, 129, 1051-1053.	0.6	0
29	The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. <i>Blood Reviews</i> , 2016, 30, 453-459.	2.8	95
30	Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria. <i>Leukemia</i> , 2016, 30, 1126-1132.	3.3	49
31	Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease. <i>American Journal of Hematology</i> , 2017, 92, 885-891.	2.0	47
32	Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis. <i>American Journal of Pathology</i> , 2017, 187, 1879-1892.	1.9	17
33	Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis. <i>American Journal of Clinical Pathology</i> , 2017, 147, 444-452.	0.4	32
34	Essential thrombocythemia following immune thrombocytopenia with JAK2V617F mutation. <i>Leukemia Research Reports</i> , 2018, 9, 14-15.	0.2	6
35	Supratentorial hemangioblastomas in von Hippel-Lindau wild-type patients: A case series and literature review. <i>International Journal of Neuroscience</i> , 2018, 128, 295-303.	0.8	13
36	Recommendations for the diagnosis and treatment of patients with polycythaemia vera. <i>European Journal of Haematology</i> , 2018, 101, 654-664.	1.1	11
37	Genomic characterization of spleens in patients with myelofibrosis. <i>Haematologica</i> , 2018, 103, e446-e449.	1.7	7
38	Late polycythemic transformation in JAK2-mutated essential thrombocythemia patients: characteristics along with a validation of 2016 WHO criteria. <i>European Journal of Haematology</i> , 2019, 103, 558-563.	1.1	2

#	ARTICLE	IF	CITATIONS
39	In situ detection of <i>JAK2</i> V617F within viable hematopoietic cells using gold nanoparticle technology. <i>International Journal of Laboratory Hematology</i> , 2019, 41, e95-e98.	0.7	2
40	Recommendations for Therapeutic Apheresis by the Section "Preparative and Therapeutic Hemapheresis" of the German Society for Transfusion Medicine and Immunohematology. <i>Transfusion Medicine and Hemotherapy</i> , 2019, 46, 394-406.	0.7	15
41	Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis. <i>Platelets</i> , 2019, 30, 322-328.	1.1	14
42	Pitfalls of delaying the diagnosis of hereditary haemorrhagic telangiectasia. <i>Journal of International Medical Research</i> , 2020, 48, 030006051986097.	0.4	2
43	The red blood cell count and the erythrocyte sedimentation rate in the diagnosis of polycythaemia vera. <i>European Journal of Haematology</i> , 2020, 104, 46-54.	1.1	5
44	Platelet microRNA expression and association with platelet maturity and function in patients with essential thrombocythemia. <i>Platelets</i> , 2020, 31, 365-372.	1.1	21
45	Parathyroid Adenoma as a Rare Cause of Persistent Hypercalcemia in a Female with Polycythemia Vera. <i>Case Reports in Oncology</i> , 2020, 13, 578-582.	0.3	1
46	Treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened Kidney Function. <i>Pharmacology</i> , 2021, 106, 316-322.	0.9	7
47	Polycythaemia vera: molecular genetics, diagnostics and therapeutics. <i>Vox Sanguinis</i> , 2021, 116, 617-627.	0.7	5
48	Volumetric splenomegaly in patients with essential thrombocythemia and prefibrotic/early primary myelofibrosis. <i>International Journal of Hematology</i> , 2021, 114, 35-43.	0.7	5
49	Genome editing to model and reverse a prevalent mutation associated with myeloproliferative neoplasms. <i>PLoS ONE</i> , 2021, 16, e0247858.	1.1	4
50	Synoptic Diagnostics of Myeloproliferative Neoplasms: Morphology and Molecular Genetics. <i>Cancers</i> , 2021, 13, 3528.	1.7	5
51	Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. <i>Journal of Clinical Investigation</i> , 2012, 122, 3888-3899.	3.9	74
52	A 7-Gene Signature Depicts the Biochemical Profile of Early Prefibrotic Myelofibrosis. <i>PLoS ONE</i> , 2016, 11, e0161570.	1.1	6
53	Retinal vessel caliber, choroidal thickness and ocular pulse amplitude measurements in essential thrombocythemia. <i>Middle East African Journal of Ophthalmology</i> , 2016, 23, 84.	0.5	2
54	Philadelphia-negative chronic myeloproliferative neoplasms. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2012, 34, 140-149.	0.7	14
55	Critical Issues About the Diagnosis of MPNs: Bone Marrow Histopathology. , 2012, , 19-35.		0
56	Literaturhinweise und Internetadressen. , 2012, , e1-e61.		0

#	ARTICLE	IF	CITATIONS
57	Therapeutic Phlebotomy. , 2013, , 529-531.		0
58	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0
59	ESSENTIAL THROMBOCYTHAEMIA : A CASE REPORT. Journal of Evolution of Medical and Dental Sciences, 2015, 4, 5059-5063.	0.1	0
60	ERITROCITOZÄ-S PASIREIÅKIMAS ÅIRDIES NEPAKANKAMUMU SERGANÅÆIAM PACIENTUI. KLINIKINIS ATVEJIS. Health Sciences, 2018, 28, 91-94.	0.0	0
61	Major Changes to the 2017 Revision of the World Health Organization Classification of Myeloproliferative Neoplasms. Korean Journal of Medicine, 2018, 93, 351-359.	0.1	2
63	Haematocrit is invalid for estimating red cell volume: a prospective study in male volunteers. Blood Transfusion, 2012, 10, 471-9.	0.3	11
64	Diagnosis and Management of Polycythemia Vera in a Ferret (). Comparative Medicine, 2016, 66, 463-467.	0.4	1
65	A randomized phase 3 trial of interferon-Î± vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood, 2022, 139, 2931-2941.	0.6	45
66	Volumetric Splenomegaly in Patients With Polycythemia Vera. Journal of Korean Medical Science, 2022, 37, e87.	1.1	5
67	Assessing Bone Marrow Activity with [ <i>18</i> F</i>]FLT PET in Patients with Essential Thrombocythemia and Prefibrotic Myelofibrosis: A Proof of Concept. Technology in Cancer Research and Treatment, 2022, 21, 153303382210863.	0.8	3
68	Osteolytic bone lesions in patients with primary myelofibrosis: A systematic review.. Acta Biomedica, 2022, 92, e2021478.	0.2	1
70	The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms. American Journal of Hematology, 2023, 98, 166-179.	2.0	27
71	International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2023, 482, 53-68.	1.4	12
72	A study on the correlation between hemoglobin concentration and the storage quality of suspended red blood cells prepared from the whole blood of Tibetan male residents. Frontiers in Medicine, 0, 9, .	1.2	0
73	Case report: Metastatic pancreatic neuroendocrine tumour associated with portal vein thrombosis; successful management with subsequent pregnancies. Frontiers in Endocrinology, 0, 14, .	1.5	1